Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Blood Adv (2024) 8 (8): 2020–2029.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals